In 2008, cervical cancer was the third most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide ([@bib11]). In Korea, it is the most common female genital malignancy, accounting for 9.8% of newly diagnosed malignancies in women ([@bib21], [@bib20]).

The definitive primary treatment for early cervical cancer consists of concurrent chemoradiation or radical hysterectomy with pelvic and/or para-aortic lymphadenectomy ([@bib18]). In selected cases, radical trachelectomy with pelvic and/or para-aortic lymphadenectomy can be used to preserve fertility ([@bib6]). Surgery is widely selected, because it removes the primary disease, preserves ovarian function, and permits better targeting of adjuvant therapy through accurate surgical staging. Although not included in the FIGO (International Federation of Gynecology and Obstetrics) staging system, lymph node metastasis (LNM) is a significant prognostic factor in early cervical cancer. Thus, information on the lymph node (LN) status is necessary to determine the treatment strategy ([@bib18]). Lymphadenectomy has been used to assess LN status in early cervical cancer; however, the therapeutic role of lymphadenectomy is debated ([@bib24]; [@bib27]; [@bib30]). Lymph node metastasis develops in only 15−25% of early-cervical cancer patients ([@bib4]); a significant portion of patients undergo lymphadenectomy unnecessarily and suffer from procedure-related morbidity. Much effort has been made to reduce the lymphadenectomy-related morbidity in these patients. Recent data suggest that sentinel LN (SLN) biopsy could be established as a method of LN staging in patients with early cervical cancer ([@bib1]; [@bib19]). However, the technique has not yet been fully validated and it involves surgery under general anaesthesia ([@bib9]; [@bib17]). Therefore, it would be very useful to identify patients with a low likelihood of LNM preoperatively. Furthermore, the ability to identify low-risk patients may be useful in clinical trial design. This study aimed to construct and validate a nomogram that could predict LNM in early-cervical cancer patients and to use the nomogram to identify patients at a low risk for LNM.

Materials and methods
=====================

Patients
--------

After obtaining institutional review board approval (S2013-0643-0001), patients were identified from a computerised database of cervical cancer patients who underwent surgery at the Asan Medical Center between March 2009 and December 2012. The inclusion criteria were as follows: pathologically confirmed cervical cancer, age \>18 years and \<80 years, a clinical diagnosis of FIGO stage IA2-IIA disease, radical hysterectomy (type II or III) or radical trachelectomy with pelvic and/or para-aortic lymphadenectomy, pelvic magnetic resonance imaging (MRI) and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) performed within 3 weeks before lymphadenectomy, and no history of chemotherapy or radiotherapy. From a database of 576 patients with FIGO stage IA2-IIA cervical cancer, 493 patients satisfied the eligibility criteria. Before analysis, patients were allocated to a model-development set (*n*=304; March 2009--August 2011) and a validation set (*n*=189; September 2011---December 2012) based on surgery dates ([Figure 1](#fig1){ref-type="fig"}).

Patients received exact staging, including physical examination, complete blood count, urinalysis, liver function test, serum squamous cell carcinoma antigen (SCC Ag), chest X-ray, intravenous pyelography, and sigmoidoscopy. Demographic and clinicopathologic data were obtained from medical records. Bilateral pelvic and/or para-aortic lymphadenectomy was performed as described previously ([@bib25]).

Preoperative assessment
-----------------------

To identify variables predicting LNM, the following factors were included based on data from previous studies ([@bib16]; [@bib33]; [@bib8]): age, FIGO stage, histology, parametrial invasion, tumour size, potential LNM based on MRI, potential LNM based on PET/CT, and pretreatment serum SCC Ag. Tumour size and parametrial invasion were assessed by MRI. The MRI criteria for metastatic LN included a short axis diameter (⩾1 cm), the presence of necrotic portions, lobulated or speculated margins, heterogeneous enhancement, or loss of fatty hilum. The settings and conditions of the PET/CT scanning process were described in [Supplementary Data](#sup1){ref-type="supplementary-material"} (online only). Scans were interpreted based on the criteria of the International Harmonization Project in Lymphoma ([@bib12]). The results of preoperative biopsy, pelvic MRI, and whole-body PET/CT were interpreted blindly without knowledge of LN involvement by pathologists, radiologists, and nuclear medicine physicians, respectively.

Statistical analysis
--------------------

Age, tumour size, and serum SCC Ag were considered as continuous variables. FIGO stage, histology, parametrial invasion, LNM assessed by MRI, and LNM assessed by PET/CT were considered as categorical variables. The histological subtype was classified as SCC or non-SCC.

The nomogram was built as described previously ([@bib10]; [@bib31]). Before developing the nomogram, low risk was defined as a predicted probability of developing LNM of \<5% ([@bib22]; [@bib3]). To develop a robust and well-calibrated nomogram predicting the risk of LNM, a logistic regression model was built using a development cohort of 304 patients and validated with a cohort of 189 patients. Grouping of categorical variables was done *a priori*. A logistic regression model was developed to predict LNM with a bootstrap method. First, the bivariate relationship between risk factors and LNM was assessed in the model-development cohort. Next, the predictive values obtained by univariate analyses were tested by bootstrap resampling, in which a logistic regression model with a backward elimination procedure included 1000 repetitions. The criterion for inclusion of predictors in the final logistic model was a 50% relative frequency of selection by bootstrap resampling. To assess the fit of the model, the concordance index was used to measure discrimination by calculating the area under the receiver operating characteristics curve, and the Hosmer--Lemeshow test was employed to assess calibration. For external validation, the model was applied on a validation cohort of 189 patients. Using the same methods, the discrimination and calibration of the model were tested. Finally, the LNM rate of groups previously identified as low risk by the nomogram was assessed in the development and validation cohorts. The negative likelihood ratio (LR−) was calculated using the following formula: LR−=(1−sensitivity)/specificity. On the basis of Bayes\' theorem, the LR− was converted into the negative post-test probability (i.e., the negative predictive value (NPV)) at an appointed prevalence of LNM ([@bib2]). All analyses were performed using SPSS version 19.0 (SPSS, Chicago, IL, USA) and R version 3.0.0 (<http://cran.r-project.org/mirrors.html>). A *P*-value \<0.05 was considered significant.

Results
=======

Patient populations
-------------------

The characteristics of the model-development and validation cohorts are summarised in [Table 1](#tbl1){ref-type="table"}. The LNM frequency for both the model-development and the validation cohort was 20.1% (6 out of 304 and 38 out of 189, respectively).

Model development for the prediction of LNM
-------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows the results of the logistic regression model for predicting LNM. Univariate analysis showed that age, stage, SCC Ag, tumour size measured by MRI, and LNM assessed by PET/CT were significantly associated with LNM. After a bootstrap resampling procedure with 1000 repetitions, the final model yielded three statistically significant predictors: age, tumour size, and LNM by PET/CT. A nomogram was constructed based on this logistic regression model ([Figure 2](#fig2){ref-type="fig"}). The point value assigned to each factor was proportional to the hazard ratio that was derived from its own *β*-coefficients by regression analysis. Internal validation was performed using the bootstrapping correction technique. After 1000 repetitions, the bootstrap-corrected concordance index for the model was 0.878 (95% confidence interval (CI), 0.833−0.917) ([Figure 3A](#fig3){ref-type="fig"}). In the validation cohort, the discrimination accuracy of the model was 0.825 (95% CI, 0.736−0.895; [Figure 3B](#fig3){ref-type="fig"}). [Figure 3C and D](#fig3){ref-type="fig"} show the calibration plots of the nomogram for the model-development and validation cohorts, respectively. The dashed line indicates the performance of an ideal nomogram and the solid line indicates the performance of the present nomogram. The filled dots were derived from a subcohort of the present database. When plotting the probabilities of LNM predicted by the nomogram against the actual probabilities, the calibration curve lay close to the dashed line. The Hosmer--Lemeshow test yielded a *P*-value of 0.566 for the model-development cohort, showing that the nomogram was well fitted. For the validation cohort, the nomogram also fitted the data well (*P*=0.411, Hosmer--Lemeshow test).

Identification of patients at low risk of nodal metastasis
----------------------------------------------------------

The low-risk group was predefined as having a predicted probability of LNM of \<5%. The nomogram classified 102 out of 304 patients (34%) in the model-development cohort as low risk. In that group, the predicted probability of LNM was 3.20% and the actual metastasis rate was 0.98% (1 out of 102). Thirteen patients were FIGO stage IA2, 76 were IB1, and three were IIA1. Only one patient with stage IB1 had LNM. In the validation cohort, 72 out of 189 patients (38%) were classified as low risk. In that group, the predicted probability of LNM was 3.21% and the actual metastasis rate was 4.17% (3 out of 72). After combining the model-development and validation cohorts, the LR− for low-risk criteria was estimated. The LR− of the study population was 0.094 (95% CI, 0.036−0.248). This LR− can be converted into a NPV of 0.984 (95% CI, 0.958−0.994) based on Bayes\' theorem, using a nodal metastasis prevalence of 15%.

[Table 3](#tbl3){ref-type="table"} shows a brief description of the four patients with metastatic LN falsely identified as low risk. There is discrepancy in tumour size between preoperative MRI and postoperative pathologic evaluation in these patients. The four patients received adjuvant concurrent chemoradiation and none have recurred to date.

Discussion
==========

The present study suggests that the risk of LNM may be determined before surgery using preoperative variables, including age, tumour size assessed by MRI, and LNM assessed by PET/CT. Incorporating these three variables, a nomogram for preoperative risk assessment of nodal metastasis was constructed, in which patients with predicted probability of LNM\<5% were defined as a low-risk group. In the model-development and validation cohorts, the actual LNM rate of the low-risk group defined by our nomogram was remarkably low. Hence, lymphadenectomy may not be performed in patients classified as low risk by this nomogram.

The most important benefit of the nomogram is that risk can be assessed by non-invasive procedures before surgery. Individualised prediction based on the nomogram, which incorporates preoperative variables, could help inform decision-making by physicians and patients. Although lymphadenectomy is the standard criterion to evaluate the nodal status of cervical cancer, the therapeutic value of this procedure is debated in the absence of level 1 evidence ([@bib24]; [@bib27]; [@bib30]). Theoretically, after complete LN removal, patients who are truly negative for LNM will not benefit from lymphadenectomy ([@bib29]). As the LNM rate in early cervical cancer is 15−25%, ∼80% of the patients might receive little benefit from lymphadenectomy and less aggressive surgery may be proposed.

Lymphadenectomy may result in morbidities such as vessel injuries, nerve injuries, infection, lymphocysts, and lymphoedema ([@bib23]). Efforts to identify node-negative patients by SLN techniques have decreased the frequency of these complications. Recent data suggest that SLN biopsy may decrease the demand for pelvic lymphadenectomy in early-cervical cancer patients ([@bib19]). However, SLN biopsy is not routinely performed, because there is a lack of consistent data on the intraoperative pathological evaluation, the role of micrometastasis in LN, and procedure standards ([@bib9]; [@bib1]).

With respect to diagnostic performance, the prediction accuracy of our nomogram was comparable to recently published data from a prospective, multicentre study of SLN biopsy. The SENTICOL study showed that given a LNM prevalence of 17.9%, the detection sensitivity was 92.0% and the NPV was 98.2% ([@bib19]). After combining the model-development and validation cohorts in our study, the sensitivity and NPV were 96.0% (95 out of 99) and 97.7% (170 out of 174), respectively, with a LNM prevalence of 20.1% (99 out of 493). Assuming a prevalence of 17.9%, as in the SENTICOL study, the NPV of our low-risk criteria would be 0.980 (95% CI, 0.949−0.992), which is similar to the performance observed in the SENTICOL study. We believe that we can more accurately identify the node-negative patients by combined use of SLN biopsy and the nomogram.

Regarding the radiologic assessment of LNM, previous studies indicate that PET/CT may be superior to CT and MRI ([@bib5]; [@bib14]). A recent meta-analysis of 41 studies reported that PET or PET/CT had an overall higher diagnostic performance than CT or MRI for LNM detection in cervical cancer patients ([@bib5]), PET or PET/CT had the highest pooled sensitivity (82%) and specificity (95%), whereas CT had 50% and 92%, and MRI had 56% and 91%, respectively. In the present study, PET/CT improved the detection sensitivity and specificity to 72.1% and 84.4%, respectively, whereas MRI had a 55.7% sensitivity and 76.1% specificity. The model was also tested using the LN status determined by MRI instead of PET/CT. The variables incorporated in the multivariate analysis were age, tumour size, SCC Ag (categorical), and LN status assessed by MRI. The concordance indices for the MRI-based model were 0.811 (95% CI, 0.753−0.863) and 0.770 (95% CI, 0.682−0.846) for the model-development cohort and validation cohort, respectively ([Table 4](#tbl4){ref-type="table"}). Although the observed metastasis rates of the predicted low-risk group using the MRI-based model were 0% (0 out of 46) and 4.2% (1 out of 24) in the development and validation cohorts, respectively, the MRI-based model predicted rates of 15.1% (46 out of 304) in the model-development cohort and 12.7% (24 out of 189) in the validation cohort. Therefore, we chose the multivariate model based on PET/CT.

The four patients incorrectly classified as low risk by our nomogram had small metastatic LN (\<7 mm in diameter). Although PET/CT could be useful in detecting LN metastases, the sensitivity of PET/CT for detecting microscopic LN metastases was much lower (34−53%) in patients with negative morphological imaging ([@bib35]; [@bib13]). [@bib32] suggested that 5 mm was the size threshold for the detection of metastatic LN by PET/CT. Recently, emerging modalities such as hybrid PET/MRI and MRI using nanoparticle contrast agents have been shown to have higher diagnostic value than PET/CT for detecting LN metastases in cervical cancer patients ([@bib28]; [@bib15]). The risk of LNM may be more accurately predicted by incorporating these modalities into the nomogram. In addition, the SLN concept could be used to confirm the results of the nomogram, particularly the case of small tumours (up to stage IB1). Thus, false-negative patients identified by the nomogram would be diagnosed as metastasised by SLN biopsy with a high probability.

These results do not indicate that routine lymphadenectomy is beneficial for non-low-risk patients. Although the actual LNM rate was 29.8% in the non-low-risk group, the therapeutic value of lymphadenectomy in this group must be evaluated in clinical trials. In addition, the role of SLN biopsy and the prognostic value of metastatic nodal resection should be assessed in this risk group and not in the entire population. Our study indicates that patients defined as low risk by our nomogram should be excluded from such trials.

This study has limitations inherent to retrospective chart reviews. Known factors associated with LNM, such as detection of human papilloma virus by genotyping and LVSI, were not included in the present study ([@bib34]; [@bib7]). Notably, three of the four patients incorrectly classified as low risk had LVSI on final pathologic examination. LVSI could not be assessed in the vast majority of the patients in our study population before surgery, because punch biopsies, not cone biopsies, were performed in 52.7% of the patients (260 out of 493). Importantly, the FIGO classification does not include LVSI, because pathologists do not always agree on whether LVSI is present ([@bib26]). If these variables can be accurately estimated and incorporated into the present model, they may increase its performance index. In addition, although we validated the model using external data from our institution and the model was well fitted, the model must be validated using data from other institutions to assess its generalisability. A multicentre prospective observational study conducted by the Korean Gynecologic Oncology Group will be used to validate the prediction model for LNM in early cervical cancer.

In conclusion, a robust model incorporating preoperative variables to predict LNM in patients with early cervical cancer was developed and validated. The model accurately identifies patients at low risk of LNM. This new tool may be useful to clinicians and patients when deciding whether lymphadenectomy should be performed, and may be useful in designing clinical trials. A prospective validation study in a heterogeneous population will be undertaken to assess the predictive accuracy of the model.
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![**Flow chart.** Illustration of patient inclusion.](bjc2013718f1){#fig1}

![**Nomogram predicting LNM in patients with early cervical cancer.**The nomogram incorporates three variables. Points for each prognostic variable were allocated according to the scale shown here. A total score was determined by adding individual parameter points and used to calculate the predicted probability of LNM. A total score of 38.7 was assigned a value of 0.05 and was defined as low risk for nodal metastasis. Abbreviations: MRI=magnetic resonance imaging; PET/CT=positron emission tomography/computed tomography.](bjc2013718f2){#fig2}

![**Performance of the nomogram for predicting LNM in patients with early cervical cancer.** (**A**) After 1000 repetitions, the bootstrap-corrected concordance index of the model was 0.878 (95% CI, 0.833−0.917) in the model-development cohort. (**B**) In the validation cohort, the bootstrap-corrected concordance index of the model was 0.825 (95% CI, 0.736−0.895). (**C**) Calibration plots of the nomogram for the model-development cohort. (**D**) Calibration plots of the nomogram for the validation cohort. Dashed line=ideal reference value where predicted probabilities match actual probabilities of LNM; solid line indicates performance of the current nomogram; filled dots indicate calculations from a subcohort of the present database; vertical bar indicates 95% CI.](bjc2013718f3){#fig3}

###### Characteristics of the model-development and validation cohorts

  **Characteristics**                               **Model-development cohort (*****n*****=304)**   **Validation cohort (*****n*****=189)**  ***P-*****value**
  ------------------------------------------------ ------------------------------------------------ ----------------------------------------- -------------------
  **Age, years**                                                                                                                              
  Median, range                                                      48 (24--77)                                   47 (22--78)                0.640
  **BMI, kg m^−2^**                                                                                                                           
  Median, range                                                   23.3 (16.0--33.8)                             23.2 (16.9--33.7)             0.802
  **Parity, *n***                                                                                                                             
  Median, range                                                        2 (0--8)                                     3 (1−10)                  0.385
  **FIGO stage, *n* (%)**                                                                                                                     
  IA2                                                                  21 (6.9)                                     28 (14.8)                 0.003
  IB1                                                                 210 (69.1)                                   115 (60.8)                  
  IB2                                                                 50 (16.4)                                     41 (21.7)                  
  IIA1                                                                 17 (5.6)                                      3 (1.6)                   
  IIA2                                                                 6 (2.0)                                       2 (1.1)                   
  **Histology, *n* (%)**                                                                                                                      
  Squamous cell                                                       212 (69.7)                                   121 (64.0)                  
  Adenocarcinoma                                                      72 (23.7)                                     61 (32.3)                  
  Adenosquamous                                                        12 (3.9)                                      4 (2.1)                   
  Small cell                                                           8 (2.6)                                       3 (1.6)                   
  Tumour size by MRI, cm (median, range)                             2.0 (0--9.0)                                 1.8 (0--7.4)                0.399
  Pretreatment SCC Ag, ng ml^−1^ (median, range)                    0.84 (0--48.4)                                1.0 (0--88.2)               0.172
  PM involvement by MRI, *n* (%)                                      51 (16.8)                                     24 (12.7)                 0.247
  LNM by PET/CT, *n* (%)                                              82 (27.0)                                     50 (26.5)                 0.917
  Collected LN, *n* (median, range)                                   33 (3--88)                                   29 (3--79)                 0.002
  PALN dissection, *n* (%)                                            142 (46.7)                                    77 (40.7)                 0.193
  LNM, *n* (%)                                                        61 (20.1)                                     38 (20.1)                 0.991
  IA2                                                                   0 (0)                                         0 (0)                    
  IB1                                                                 30 (14.3)                                     14 (12.2)                  
  IB2                                                                 24 (48.0)                                     20 (48.8)                  
  IIA1                                                                 6 (35.3)                                     2 (66.7)                   
  IIA2                                                                 1 (16.7)                                      2 (100)                   

Abbreviations: BMI=body mass index; FIGO=International Federation of Gynecology and Obstetrics; LN=lymph node; LNM=LN metastasis; MRI=magnetic resonance imaging; PALN=para-aortic LN; PET/CT=positron emission tomography/computed tomography; PM=parametrial; SCC Ag=squamous cell carcinoma antigen.

###### Univariate and multivariate logistic regression model for predicting LNM

                                                      **Univariate analysis**   **Multivariate analysis**                           
  --------------------------------------------------- ------------------------- --------------------------- ----------------------- ---------
  Age, years[a](#t2-fn1){ref-type="fn"}               0.970 (0.947--0.994)      0.015                       0.969 (0.939--0.999)    0.043
  BMI, kg m^−2^ [a](#t2-fn1){ref-type="fn"}           0.941 (0.859--1.031)      0.193                                                
  Parity, *n*^a^                                      0.857 (0.684--1.074)      0.180                                                
  **FIGO stage**                                                                                                                    
  IA2, IB1                                            1                                                                              
  IB2, IIA                                            4.806 (2.637--8.761)      \<0.001                                              
  **Histology**                                                                                                                     
  Squamous cell                                       1                                                                              
  Adenocarcinoma                                      1.329 (0.698--2.530)      0.386                                                
  Adenosquamous                                       0.391 (0.049--3.116)      0.375                                                
  Small cell                                          2.580 (0.592--11.245)     0.207                                                
  Squamous *vs* non-squamous                          1.272 (0.701--2.309)      0.429                                                
  Pretreatment SCC Ag, ng ml^−1^                      1.064 (1.014--1.115)      0.011                                                
  **Pretreatment SCC Ag, ng ml^−1^ (categorical)**                                                                                  
  \<2                                                 1                         \<0.001                                              
  ⩾2                                                  5.035 (2.722--9.314)      \<0.001                                              
  ⩾2 and \<5                                          4.375 (2.009--9.528)      \<0.001                                              
  ⩾5                                                  5.859 (2.640--13.003)     \<0.001                                              
  Tumour size by MRI, cm[a](#t2-fn1){ref-type="fn"}   1.802 (1.485--2.187)      \<0.001                     1.584 (1.287--1.951)    \<0.001
  **PM involvement by MRI**                                                                                                         
  Yes                                                 2.375 (1.219--4.627)      0.011                                                
  **LNM by PET/CT**                                                                                                                 
  Yes                                                 13.963 (7.230--26.964)    \<0.001                     9.584 (4.772--19.249)   \<0.001

Abbreviations: BMI=body mass index; CI=confidence interval; FIGO=International Federation of Gynecology and Obstetrics; LN=lymph node; LNM=LN metastasis; MRI=magnetic resonance imaging; PET/CT=positron emission tomography/computed tomography; PM=parametrial; SCC Ag=squamous cell carcinoma antigen.

Continuous variable.

###### Brief description of patients with nodal metastasis falsely classified as low risk

  **Characteristics**                           **Patient 1**                     **Patient 2**                     **Patient 3**                     **Patient 4**
  ----------------------------------- --------------------------------- --------------------------------- --------------------------------- ---------------------------------
  **Preoperative assessment**                                                                                                               
  Age, years                                         62                                47                                46                                32
  FIGO stage                                         IB1                               IB1                               IB1                               IB1
  Histology                                       Squamous                          Squamous                          Squamous                          Squamous
  Serum SCC Ag (ng ml^−1^)                          0.83                              0.35                               1.4                               0.9
  Tumour size by MRI (cm)                             2                   0[a](#t3-fn1){ref-type="fn"}      0[a](#t3-fn1){ref-type="fn"}      0[a](#t3-fn1){ref-type="fn"}
  PM invasion by MRI                               Absent                            Absent                            Absent                            Absent
  LNM by PET/CT                                    Absent                            Absent                            Absent                            Absent
  **Postoperative assessment**                                                                                                              
  Histology                                       Squamous                          Squamous                          Squamous                          Squamous
  Tumour size (cm)                                   4.0                               1.5                               1.5                               1.3
  Depth of stromal invasion (mm)                      6                                 2                                10                                 6
  LVSI                                             Present                           Absent                            Present                           Present
  PM invasion                                      Present                           Absent                            Absent                            Absent
  LNM                                           Yes (1 of 34)                     Yes (1 of 25)                     Yes (1 of 18)                     Yes (4 of 42)
  Location of metastatic LN                     Left external                    Right external                    Right internal             Left obturator Right external
  Largest diameter of metastatic LN                0.7 mm                             6 mm                             \<1 mm                             7 mm
  Para-aortic LNM                                No (0 of 1)                           NA                            No (0 of 1)                       No (0 of 1)
  Adjuvant treatment                   CCRT[b](#t3-fn3){ref-type="fn"}   CCRT[b](#t3-fn3){ref-type="fn"}   CCRT[b](#t3-fn3){ref-type="fn"}   CCRT[b](#t3-fn3){ref-type="fn"}
  Recurrence                                         No                                No                                No                                No
  Progression-free survival                       21 months                         32 months                         6 months                          40 months

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; LN=lymph node; LNM=LN metastasis; LVSI=lymphovascular space invasion; MRI=magnetic resonance imaging; NA, not applicable; PET/CT=positron emission tomography/computed tomography; PM=parametrial; SCC Ag=squamous cell carcinoma antigen.

No visible residual tumour in the uterine cervix.

Concurrent chemoradiation (weekly cisplatin regimen).

###### Performance of each multivariate model based on MRI or PET/CT data

                                                 **Model-development set**   **Validation set**                                                  
  ---------------------------------------------- --------------------------- -------------------- --- ------- ---------------------- ------- --- -------
  Model with MRI[a](#t4-fn2){ref-type="fn"}      0.811 (0.753--0.863)        7.609                8   0.473   0.770 (0.682--0.846)   3.314   6   0.768
  Model with PET/CT[b](#t4-fn3){ref-type="fn"}   0.878 (0.833--0.917)        6.734                8   0.566   0.825 (0.736--0.895)   6.107   6   0.411

Abbreviations: AUC=area under the receiver operating characteristics curve; CI=confidence interval; DF=degree of freedom; LNM=lymph node metastasis; MRI=magnetic resonance imaging; PET/CT=positron emission tomography/computed tomography; SCC Ag=squamous cell carcinoma antigen.

Variables incorporated are age, tumour size by MRI, LNM assessed by MRI, SCC Ag (categorical; \<2 ng ml^−1^ *vs* ⩾2 ng ml^−1^).

Variables incorporated are age, tumour size by MRI, LNM assessed by PET/CT.
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